If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
90
results.
Updated on
11/09/2025 [07:13:00]
Absstract of: CN120605324A
本发明涉及一种猪源细菌多糖‑病毒蛋白结合疫苗及其制备方法和应用，属于动物疫苗技术领域。该疫苗以猪源细菌多糖和病毒蛋白为原料，通过生物素‑亲和素体系偶联形成多糖‑病毒蛋白结合物；其中病毒蛋白选自猪瘟病毒E2蛋白、猪圆环病毒2型Cap蛋白、猪伪狂犬病毒gD蛋白等蛋白中的一种，猪源细菌多糖选自猪链球菌荚膜多糖、猪多杀性巴氏杆菌荚膜多糖等多糖中的一种。该疫苗能同时诱导机体产生针对猪源细菌荚膜多糖和病毒蛋白的高水平IgG抗体，实现对猪源细菌和病毒感染的协同免疫保护，具有广谱交叉免疫效果。
Absstract of: AU2024220779A1
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Absstract of: US2025277250A1
The invention relates to a gelled reaction medium for the detection, identification, enumeration and/or isolation of at least one target microorganism in a simple that may contain same, comprising at least one binding partner specific to a component of a target microorganism or of a component derived from said microorganism, coupled to at least one nanoparticle to form at least one binding conjugate.
Absstract of: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Absstract of: CN120550103A
一种基于细菌外膜囊泡的口服疫苗制备方法及其应用，可有效应用于制备预防或治疗肠道黏膜病原体感染的药物，克服传统注射型疫苗依从性差、黏膜免疫反应低的问题。首先制备粪产碱杆菌的细菌外膜囊泡，然后制备DSPE‑PEG‑antigen，将两者混合后搅拌，制得OMV‑DSPE‑PEG‑antigen，取菊粉溶于PBS中，加热振荡，冷却至室温，加入OMV‑DSPE‑PEG‑antigen，搅拌，放置，得成品口服疫苗。制备工艺简单，方法稳定可靠，易操作，生产成本低，制备的基于细菌外膜囊的口服疫苗可有效激发肠道黏膜免疫应答，预防黏膜病原体的感染，经济和社会效益显著。
Absstract of: WO2024155027A1
The present invention relates to an attenuated Salmonella gallinarum expressing FliC or FliC-hiL2 and use thereof. The Salmonella strain according to the present invention has excellent immune activity and exhibits excellent anti-cancer efficacy, and thus can be used as a therapeutic agent for cancer together with or independently of existing anti-cancer drugs.
Absstract of: WO2025171792A1
Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.
Absstract of: US2025261659A1
Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.
Absstract of: WO2025175111A1
Two stage heated water treatment of shell eggs results in-shell poached eggs. The in-shell poached are sufficiently cooked so when the eggs are cracked onto a plate the eggs have the characteristics of conventional poached eggs without further cooking and need only to be warmed for consumption. The in-shell poached eggs are also pasteurized in the shell to meet the FDA and WHO requirement of a 5-log reduction of Salmonella Enteritidis.
Absstract of: CN120051482A
The present invention relates to a modified live attenuated Gram-negative bacterium wherein the bacterium has been modified such that an RNA molecule can be safely and efficiently delivered to a target eukaryotic cell. Thus, the present invention relates to a bacterial delivery system and various uses and methods thereof.
Absstract of: WO2025170108A1
The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.
Absstract of: CN120484133A
本发明提供了一种基于猪圆环病毒2型(PCV2)纳米抗体与沙门氏菌鞭毛蛋白的重组融合蛋白及其制备方法与应用。本发明将PCV2衣壳蛋白(Cap)特异性纳米抗体基因与沙门氏菌鞭毛蛋白基因融合，使用大肠杆菌原核表达系统表达制备了Nbcap‑flagellin重组融合蛋白。该重组融合蛋白能够利用Cap蛋白特异性纳米抗体的靶向结合能力，实现鞭毛蛋白佐剂与抗原蛋白的动态偶联，形成佐剂用量可调控的抗原‑佐剂复合物；在充分发挥鞭毛蛋白作为免疫佐剂作用的同时，突破传统鞭毛蛋白与抗原蛋白融合表达导致的固定佐剂‑抗原配比限制，提升了疫苗设计的灵活性，避免了细菌鞭毛蛋白过量可能引发的炎性反应，为开发高效、安全且广谱的PCV2亚单位疫苗提供了新的技术路径。
Absstract of: KR20250122779A
구현예의 수의학적 조성물은 가금류의 대장균 또는 살모넬라균에 의한 설사 증상의 치료 또는 완화용도를 갖는 것으로, 색도 L이 77 이하인 액상이고, 유효성분 및 항산화제를 포함하고, 상기 유효성분은 아프라마이신 또는 이의 염을 유효성분을 포함한다. 구현예의 수의학적 조성물은 조류의 대장균증 또는 추백리의 치료 또는 완화용으로 그 효과가 우수하다. 또, 구현예의 수의학적 조성물은 아프라마이신 또는 이의 염을 유효성분으로 포함하는 액상 조성물로 유효성분에 대한 조성물의 보관 안정성이 우수하고, 투여가 용이한 장점도 있다.
Absstract of: WO2025170108A1
The present invention relates to identifying and engineering a tail spike protein gene from a genome of bacteriophage SFP10 infected with a Salmonella strain, purifying and producing a recombinant protein using mSFP10TSP, which is a recombinant protein formulation for detecting Salmonella enterica, EGFP-mSFP10TSP fused with a green fluorescent protein, and SiBD-mSFP10TSP fused with an SiBD, and thereby specifically detecting the Salmonella strain.
Absstract of: WO2025170306A1
The present invention relates to an antibacterial composition comprising, as an active ingredient, a plantaricin peptide derived from a Lactiplantibacillus plantarum KM2 strain, wherein the plantaricin peptide derived from the strain and a plantaricin peptide combination were found to have antimicrobial activity against at least one selected from the group consisting of Flavobacterium sp, Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus, and acromobacter xylosoxidans (Alcaligenese xylosoxidans), Salmonella enterica, <i />and Vibrio parahaemolyticus, and the plantaricin peptide and the plantaricin peptide combination were found to have antibacterial activity and a cell wall lysis effect against the Flavobacterium sp. strain, and accordingly, the plantaricin peptide derived from the Lactiplantibacillus plantarum KM2 strain and the plantaricin peptide combination are provided as antimicrobial agents.
Absstract of: KR20250121896A
본 발명은 사람에서 세균성 식중독을 일으키는 주요 원인균인 S. Enteritidis 및 S. Typhimurium, 그리고 가금에서 폐사를 일으키는 가금티푸스 원인균인 S. Gallinarum에 대한 산란계에서의 효과적인 살모넬라균 감염 예방을 위한 최적의 예방 프로그램 확립을 위한 발병을 수행하였다. 약독화 생균 백신만을 접종한 경우와 3가 살모넬라 불활화 사균체 백신만을 단독 접종한 산란계 모두에서 폐사는 발생하지 않았지만, 내부 장기 및 맹장 그리고 총 배설강 등에서 도전감염 균주가 분리되었다. 하지만 시판 백신인 약독화 생균 백신인 SG9R을 1차로 피하 접종한 후, 3가 살모넬라 불활화 사균체 (살모넬라 엔터라이티디스, 살모넬라 타이피뮤리움, 살모넬라 갈리나룸 불활화 사균체) 백신으로 추가로 근육 접종할 경우에는 내부 장기 및 맹장과 총배설강 등지에서 도전감염 균주가 분리되지 않았다. 이를 통해 약독화 생균 백신 및 3가 살모넬라 불활화 사균체 백신을 단독으로 접종한 경우보다 약독화 생균 백신 접종 후, 3가 살모넬라 불활화 사균체 백신을 추가로 접종할 경우 산란계에서 주요 살모넬라균을 효과적으로 예방할 수 있음이 확인하였다.
Absstract of: WO2025165867A1
Provided herein are compositions comprising in vivo succinate-producting microorganisms, e.g., Bacteroides and Prevotella species (preferably Bacteroides thetaiotaomicron (e.g., VPI 5482), Bacteroides vulgatus (e.g., NCTC 11154, Prevotella copri (e.g., DSM 18205)), Parabacteroides (e.g., Parabacteroides distasonis), and Bacilli (e.g. Lactobacillus animalis), and methods of use thereof in treating or reducing risk of developing an intestinal infection, optionally an infection with Campylobacter, Salmonella, E. coli, Shigella, Listeria monocytogenes, Vibrio, Enteropathogenic E. coli, Klebsiella, or Clostridioides difficile, or promoting expansion of colonic tuft cells, in a subject.
Absstract of: KR20250117498A
본 발명은 살모넬라 균 (Salmonella spp.) 검출용 조성물 및 이를 이용한 검출방법에 관한 것으로서, 보다 상세하게는 살모넬라 균 InvA 유전자 서열을 증폭하기 위한 프라이머 세트와 프로브에 관한 것으로, 식용 갈색거저리 내 유해균인 살모넬라 균을 특이적으로 검출 할 수 있다.
Absstract of: MX2025007790A
Methods and antimicrobial compositions are provided for surface cleaning. The antimicrobial compositions which include very low concentrations of an organic acid and one or more anionic surfactants can, unexpectedly, provide effective and broad spectrum antimicrobial activity within two minutes of contact with a surface and in some instances within one minute of contact time. Contacting the antimicrobial compositions with a surface can result in greater than or equal to about 4.0 log kill or 5.0 log kill for one or more of <i>Staphylococcus aureus</i>, <i>Pseudomonas aeruginosa</i>, and <i>Salmonella enterica </i>on the surface in two minutes or less. The compositions can have antimicrobial activity against at least one gram-positive bacterium, gram-negative bacterium, virus, and fungus in two minutes or less of contacting the composition with a surface.
Absstract of: CN119907682A
Provided herein are vaccine compositions comprising a Salmonella antigen conjugated to a capsid wherein the capsid comprises a wild-type or native sequence. Also provided herein are vaccine compositions comprising a Salmonella antigen conjugated to a capsid wherein the capsid comprises at least one mutation, such as a non-natural mutation. Such compositions are useful in the prevention or treatment of Salmonella infection (salmonellosis), in the treatment and prevention of gastroenteritis, typhoid and/or paratyphoid; and the method can effectively aim at various salmonella strains.
Absstract of: CN119923470A
The present invention relates to a modified live attenuated Salmonella strain comprising at least one chromosomal integrated synthetic polynucleotide sequence inserted in a predetermined pseudogenomic position, said sequence comprising at least one defined recombination site for introducing a heterologous polynucleotide sequence encoding a polypeptide, wherein the chromosome integration synthetic polynucleotide sequence is located within at least one genomic site, the genomic site being defined by any one of SEQ ID NO: 1-30 or a sequence having at least 70% identity with any one of SEQ ID NO: 1-30. The invention also relates to vaccine compositions comprising the modified strains and various uses and methods thereof.
Absstract of: GB2637451A
Disclosed are a lactobacillus farciminis SR2 and a use thereof. The present lactobacillus farciminis SR2 shows good tolerance under an acidic condition of pH = 3.0, has strong adaptability in 45 C° high-temperature and high salt (10% NaCl) environment, inhibits the growth of harmful bacteria such as escherichia coli, staphylococcus aureus, and salmonella, has high productivity of ferulic acid esterase, can significantly lower the pH level of rice straw silage feed, significantly increase the content of lactic acid, significantly reduce the content of ammonia nitrogen, significantly increase the content of dry matter and WSC, significantly reduce the content of NDF, ADF and cellulose, improve the fermentation quality of the rice straw silage feed, and the method can be widely applied to the field of rice straw fermentation feed preparation.
Absstract of: CN119630803A
The present invention relates to an extracellular vesicle containing an antigen protein or a gene encoding the protein, and a use thereof, and more specifically, to an extracellular vesicle containing an antigen protein derived from a virus, a microorganism or a cancer cell or a gene encoding the protein, or a vaccine composition for preventing or treating viral infections, microbial infections or cancers comprising the same. The extracellular vesicle or the vaccine composition comprising the same according to the present invention is a platform applicable to various diseases, has excellent antigen-specific immune response induction effect and stability, and is expected to be effectively used in the field of vaccine development. The vaccines are useful for the prevention or treatment of various diseases including viral infections, microbial infections or cancers.
Absstract of: CN120366177A
本发明提供一种四基因敲除减毒鼠伤寒沙门氏菌及其构建方法和应用，所提供的一种四基因敲除减毒鼠伤寒沙门氏菌，是敲除了鼠伤寒沙门氏菌的relA、Asd、manA和sifA基因。本发明构建了四种毒力因子缺失的鼠伤寒沙门氏菌的减毒菌株ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028，可在体外稳定传代。并经安全性评价试验检测，该菌株毒力无毒力，安全性极高。为了进一步评价ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028是否能够抵抗亲本株的攻击，进行了免疫效力评价，结果显示，ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028能够提供有效的免疫保护。因此，本发明的ΔrelA‑ΔAsd‑ΔmanA‑ΔsifA SM14028可作为一种有效的活疫苗或者活载体疫苗，为动物疫病的防控奠定基础。
Nº publicación: WO2025152055A1 24/07/2025
Applicant:
LANZHOU INST OF BIOLOGICAL PRODUCTS CO LTD [CN]
CHINA NAT BIOTEC GROUP COMPANY LIMITED [CN]
\u5170\u5DDE\u751F\u7269\u5236\u54C1\u7814\u7A76\u6240\u6709\u9650\u8D23\u4EFB\u516C\u53F8,
\u4E2D\u56FD\u751F\u7269\u6280\u672F\u80A1\u4EFD\u6709\u9650\u516C\u53F8
Absstract of: WO2025152055A1
Provided is a method for testing the in-vitro bactericidal function of a typhoid vaccine immune serum, comprising: testing the in-vitro bactericidal function of a typhoid vaccine immune serum against Salmonella typhi bacteria by means of an opsonophagocytic killing assay, wherein when the phagocytic killing step of the opsonophagocytic killing assay is completed, the Salmonella typhi bacteria having undergone the phagocytic killing step are cultured at the pH of 7.5-9.5. The opsonophagocytic killing assay is applied to Gram-negative Salmonella Typhi bacteria for the first time, and the in-vitro bactericidal levels of typhoid vaccine immune serums are effectively and accurately evaluated.
BOPI
Electronic site
